RA
HOWL icon

Royce & Associates’s Werewolf Therapeutics HOWL Stock Holding History

Royce & Associates’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-125,484
Closed -$306K – 879
2024
Q2 		$306K Buy
125,484
+88,163
+236% +$423K ﹤0.01% 826
2024
Q1 		$242K Buy
+37,321
New +$217K ﹤0.01% 822

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Royce & Associates's HOWL Position: Q3 2024 in Review

Royce & Associates sold out of Werewolf Therapeutics (HOWL) in Q3 2024, closing a stake of 125,484 shares — an estimated $306K sold.

Royce & Associates first reported a position in HOWL in Q1 2024 and held it in 2 quarters. The position peaked at $306K in Q2 2024. 69 funds tracked by Wall St. Rank hold HOWL as of Q3 2024.

  • Royce & Associates reported no remaining Werewolf Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Royce & Associates sold 125,484 Werewolf Therapeutics shares in Q3 2024, an estimated $306K.
  • Royce & Associates first reported a position in Werewolf Therapeutics in Q1 2024 and held it in 2 quarters.
  • Royce & Associates's Werewolf Therapeutics position peaked at $306K in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2024.

Based on Royce & Associates's 13F filing for Q3 2024, filed 6 Nov 2024.